3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Gastrointestinal
1
Conditions
Breast Neoplasms
41
Stomach Neoplasms
3
Wilms Tumor
1
Urinary Bladder Neoplasms
1
Triple Negative Breast Neoplasms
1
Sarcoma, Synovial
1
Rhabdomyosarcoma
1
Pleuropulmonary blastoma
1
Patient Preference
1
Pancreatic Neoplasms
1
Neurofibrosarcoma
1
Neuroblastoma
1
Multiple Myeloma
1
Lymphoma
1
Inflammatory Breast Neoplasms
1
Hematologic Neoplasms
1
HER2-positive Breast Cancer
1
HER2 Positive Breast Cancer
1
Esophageal Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Advanced Unresectable or Metastatic Solid Malignancy
1
Interventions
Gemcitabine
47
Cisplatin
32
pembrolizumab
28
Paclitaxel
13
Docetaxel
13
avelumab
12
Mitomycin
12
atezolizumab
11
Nivolumab
11
Cystectomy
10
Carboplatin
9
durvalumab
7
Sunitinib
7
apaziquone
6
Doxorubicin
6
BCG Vaccine
6
5-aminolevulinic acid hexyl ester
6
Vinblastine
5
Radiation
5
Platinum
5
Methotrexate
5
Magnetic Resonance Spectroscopy
5
Albumin-Bound Paclitaxel
5
Taxes
4
Standard of Care
4
Sorafenib
4
Radiotherapy
4
Fluorouracil
4
Erlotinib Hydrochloride
4
1,2-diaminocyclohexaneplatinum II citrate
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Urinary Bladder Neoplasms
×
Ado-Trastuzumab Emtansine
×
Clear all
NCT02999672
2019-08-28
KAMELEON
Hoffmann-La Roche
Phase 2
Completed
20 enrolled
14 charts